Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jami Rubin
Pharma
Cool it, analyst urges ‘overly punitive’ BMS investors
There’s no denying Bristol-Myers’ Opdivo had a tough week. But the way one analyst sees it, investors are overreacting.
Carly Helfand
Oct 23, 2018 11:23am
Was last week's Teva sell-off warranted? Depends who you ask
Oct 2, 2018 11:13am
'Action-oriented' Teva CEO Schultz has analysts impressed
Jun 27, 2018 12:16pm
Time to panic about AbbVie's ex-U.S. Humira sales?
May 25, 2017 10:05am
